Human MIP1 beta neutralizes the of bioactivity of recombinant, human MIP1 beta, but not that of recombinant, mouse MIP1 beta, recombinant, human MIP1 alpha or recombinant, mouse MIP1 beta.
In indirect ELISA and immunoblotting, this antibody displays approximately 8% cross-reactivity with recombinant, mouse MIP1 alpha, recombinant, human MIP1 alpha and recombinant, mouse MIP1 beta.
The product shows no cross-reactivity with other tested cytokines using indirect ELISA.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ELISA: Use at a concentration of 0.125 µg/ml to detect 1ng/well of recombinant human MIP1 beta.
Neut: Use at a concentration of 30 µg/ml.
WB: Use at a concentration of 1 µg/ml to detect 2ng/lane of recombinant human MIP1 beta under non-reducing conditions. Predicted molecular weight: 11 kDa.
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 isoform B.
Belongs to the intercrine beta (chemokine CC) family.
N-terminal processed form MIP-1-beta(3-69) is produced by proteolytic cleavage after secretion from peripheral blood lymphocytes.
Schmidt J et al. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain131:1228-40 (2008).
Read more (PubMed: 18420712) »